Levonorgestrel/Etinilestradiol Cinfalab

Ethinylestradiol and Levonorgestrel, the active ingredients in Levonorgestrel/Etinilestradiol Cinfalab, are a combined oral contraceptive presented as an oral tablet for oral use. Approved in the European Union, the formulation provides reliable hormonal contraception to prevent pregnancy in women of reproductive age.

GNH USA supplies Levonorgestrel/Etinilestradiol Cinfalab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products through a robust supply chain and compliance with Good Distribution Practice.

Levonorgestrel/Etinilestradiol Cinfalab is a combined oral contraceptive that acts on the hormonal regulation pathway to prevent pregnancy. - Contraception (prevention of pregnancy): Provides reliable hormonal birth control for women of reproductive age. - Menstrual cycle regulation: Helps to achieve more predictable menstrual bleeding patterns. - Dysmenorrhea relief: Reduces the severity of menstrual cramps associated with ovulatory cycles.

Levonorgestrel/Etinilestradiol Cinfalab may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional mild to moderate pain. - Weight gain: modest increase in body weight. - Mood changes: fluctuations in emotional state. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Arterial thrombosis: clot formation in arteries. - Hypertension: elevated blood pressure. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Liver dysfunction: abnormal liver enzyme levels. - Visual disturbances: sudden vision changes or loss.

Before prescribing Levonorgestrel/Etinilestradiol Cinfalab, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular risk: evaluate history of thromboembolic disorders before use. - Screen for smoking status: advise against use in women over 35 who smoke heavily. - Check hepatic function: use with caution in patients with liver disease. - Monitor blood pressure: observe for hypertension during therapy. - Avoid in pregnancy: contraindicated for women who are or may become pregnant. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Levonorgestrel/Etinilestradiol Cinfalab can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy. - Antiretroviral protease inhibitors (e.g., ritonavir): may increase hormone levels and risk of side effects. - St. John’s wort: may decrease contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., rifampin): may lower hormone levels, advise backup contraception. - Diuretics (e.g., spironolactone): may increase risk of hypertension. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood changes.